研究单位：[1]The First Affiliated Hospital of Guangzhou Medical University[2]Department of Thoracic Surgery, Beijing Cancer Hospital,Beijing, China[3]Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University,Beijing, China[4]Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University,Changsha, China[5]Department of Thoracic Surgery, Xiangya Hospital, Central South University,Changsha, China[6]Department of Thoracic Surgery, West China Hospital of Sichuan University,Chengdu, China[7]Department of Thoracic Surgery, Nanfang Hospital of Southern Medical University,Guangzhou, China[8]Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University,Guangzhou, China[9]Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-sen University,Guangzhou, China[10]Department of Thoracic Surgery, The Forth Affiliated Hospital of Harbin Medical University,Haerbin, China[11]Department of Thoracic Surgery, Anhui Chest Hospital,Hefei, China[12]Department of Thoracic Surgery, The Second Hospital，University of South China,Hengyang, China[13]Department of Thoracic Surgery, Qilu Hospital of Shandong University,Jinan, China[14]Department of Thoracic Surgery, Jiangsu Province Hospital,Nanjing, China[15]Department of Thoracic Surgery, Shenzhen People's Hospital,Shenzhen, China
Current state-of-the-art lung cancer early screening utilizes low-dose CT scan to identify lung nodules smaller than 3 cm in diameter. However, it's still a clinical challenge to differentiate between malignant and benign nodules.
In previous studies, the investigators had taken the approach of methylation profiling by high throughput bisulfite DNA sequencing in tissue samples to identify specific methylation signatures. The investigators had learned methylation patterns that differentiate malignant vs. benign lesions from tissue samples by in-depth data mining, and then used pattern matching to classify plasma samples.
In this study, the investigators are going to validate the efficacy of ctDNA methylation test for diagnosing early lung cancer by comparing results of the pre-surgery ctDNA methylation test with the post-surgery pathology.
